News
Antibacterial drugs are important to treat infections. But increasing bacterial resistance to current drugs — making them ineffective or only partially effective — means that new ones are urgently needed. Building on previous work, researchers from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), together with an international team of collaborators, have demonstrated a potential antibacterial treatment from a biosynthetic derivative of darobactin, a bacterial natural product. The team reports proof-of-concept animal trials on infections caused by bacteria, including Escherichia coli and Acinetobacter baumannii that are known to develop drug-resistance. This ACS Infectious Diseases study was published during the World Health Organization’s World Antimicrobial Resistance (AMR) Awareness Week from 18 to 24 November 2024. The HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in cooperation with Saarland University.